Work

343 Translational phase I trial combining the AKT inhibitor AZD5363 (AZD) and PARP inhibitor Olaparib (Ola) in advanced cancer patients (pts)

Year: 2015

Type: article

Source: European Journal of Cancer

DOI: 10.1016/s0959-8049(16)30206-4

Authors: V. Michalarea, J. Lopez, D. Lorente, S. Carreira, H. Hassam, M. Parmar, A. Turner, E. Hall, S. Serrano Fandos, S. Decordova, K. Swales, R. Ruddle, F. Raynaud, N. Tunariu, C.M. Stephens, L.R. Molife, U. Banerji, R. Plummer, J. De Bono, T.A. Yap

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2507224706

FWCI: 0.146

Cites:

Cited by: 1

Related to: 10